See more : Munawla Cargo Co. Ltd. (9571.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Alvotech (ALVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alvotech, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hindustan Aeronautics Limited (HAL.NS) Income Statement Analysis – Financial Results
- Hotel Shilla Co.,Ltd (008770.KS) Income Statement Analysis – Financial Results
- Warner Music Group Corp. (WMG) Income Statement Analysis – Financial Results
- New Klondike Exploration Ltd. (URPLF) Income Statement Analysis – Financial Results
- Iberdrola, S.A. (IBE1.DE) Income Statement Analysis – Financial Results
Alvotech (ALVO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alvotech.com
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 91.43M | 83.03M | 36.77M | 66.62M | 31.92M |
| Cost of Revenue | 160.86M | 64.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.42M | 18.93M | 36.77M | 66.62M | 31.92M |
| Gross Profit Ratio | -75.93% | 22.80% | 100.00% | 100.00% | 100.00% |
| Research & Development | 210.83M | 180.62M | 191.01M | 148.07M | 95.56M |
| General & Administrative | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Other Expenses | -1.95M | -1.99M | -2.91M | -2.83M | -50.76M |
| Operating Expenses | 285.44M | 365.38M | 272.23M | 204.15M | 93.37M |
| Cost & Expenses | 446.46M | 429.47M | 272.23M | 204.15M | 93.37M |
| Interest Income | 4.82M | 2.55M | 51.57M | 215.00K | 1.74M |
| Interest Expense | 134.82M | 188.42M | 117.36M | 97.47M | 95.76M |
| Depreciation & Amortization | 24.21M | 20.41M | 18.20M | 16.42M | 14.61M |
| EBITDA | -484.86M | -439.80M | 3.99M | -125.67M | -99.02M |
| EBITDA Ratio | -530.29% | -392.72% | -457.17% | -188.65% | -150.74% |
| Operating Income | -354.86M | -346.44M | -235.46M | -137.54M | -61.45M |
| Operating Income Ratio | -388.11% | -417.25% | -640.31% | -206.46% | -192.52% |
| Total Other Income/Expenses | -296.19M | -205.21M | 86.26M | -154.23M | -147.94M |
| Income Before Tax | -651.05M | -551.65M | -149.20M | -291.77M | -209.39M |
| Income Before Tax Ratio | -712.04% | -664.40% | -405.74% | -437.99% | -656.01% |
| Income Tax Expense | -99.32M | -38.07M | -47.69M | -121.73M | 491.00K |
| Net Income | -551.73M | -513.58M | -101.50M | -170.04M | -209.88M |
| Net Income Ratio | -603.42% | -618.55% | -276.04% | -255.26% | -657.55% |
| EPS | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| EPS Diluted | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| Weighted Avg Shares Out | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
| Weighted Avg Shares Out (Dil) | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
test
3 mid-caps under $20 that Wall Street loves
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar to Stelara
Source: https://incomestatements.info
Category: Stock Reports